Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Adial Pharmaceuticals ( (ADIL) ) is now available.
On September 2, 2025, Adial Pharmaceuticals received a letter from Nasdaq granting an additional 180-day extension until March 2, 2026, to comply with the minimum bid price requirement of $1.00 per share for continued listing. The company plans to monitor its stock price and may implement a reverse stock split to meet compliance, ensuring its Nasdaq listing remains unaffected in the short term.
The most recent analyst rating on (ADIL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addictions and related disorders. Its lead investigational product, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) and potentially other addictive disorders such as Opioid Use Disorder, gambling, and obesity.
Average Trading Volume: 8,968,559
Technical Sentiment Signal: Sell
Current Market Cap: $8.29M
Learn more about ADIL stock on TipRanks’ Stock Analysis page.